PTGX — Protagonist Therapeutics Share News
0.000.00%
Last trade - 00:00- $8.84bn
- $8.05bn
- $46.02m
Brief: Turnstone Biologics Appoints William Waddill To Its Board Of Directors
Brief: Protagonist Therapeutics Inc Closing Of Worldwide Collaboration And License Agreement For Rusfertide With Takeda
Brief: Protagonist Therapeutics Inc Cash Runway Extended Through Q4 2027
Brief: Protagonist Therapeutics Entered Into A License And Collaboration Agreement With Takeda Pharmaceuticals USA
Brief: Protagonist Therapeutics-Eligible To Get $60M In Milestone Payments In Q4
Protagonist Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Protagonist Therapeutics Inc expected to post a loss of 65 cents a share - Earnings Preview
Brief: Protagonist No Longer In Compliance With Nasdaq's Audit Committee Composition Requirements
U.S. RESEARCH ROUNDUP-Dice Therapeutics, Mongodb, Valvoline
Brief: Protagonist Reports Positive Results From Phase 1 And Pre-Clinical Studies Of Oral Interleukin-23 Receptor Antagonist JNJ-2113
Protagonist Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Protagonist Therapeutics Inc expected to post a loss of 73 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Allete, Gilead Sciences, Arcutis
U.S. STOCKS ON THE MOVE-FedEx, Liminal Biosciences, Kura Sushi
Protagonist Therapeutics slips on pricing $100 mln stock offering
Brief: BVF Inc Reports 9.6% Passive Stake In Protagonist Therapeutics Inc Common Stock As Of March 10 - SEC Filing
Brief: Protagonist Therapeutics - Net Loss Was $0.69 Per Share, For Q4 2022
Protagonist Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Protagonist Therapeutics Inc Exposure To Any Liquidity Concern At SVB Is Limited